Elliann Dunbar

Associate

  • Elliann Dunbar
  • Phone: +1 212 404 8753

    Import to Address Book

  • Duane Morris LLP
    22 Vanderbilt
    335 Madison Avenue, 23rd Floor
    New York, NY 10017-4669
    USA

Elliann Dunbar is an associate in the firm's Corporate Practice Group. Her work primarily focuses on public and private securities offerings and public company representation. Ms. Dunbar has experience representing underwriters, placement agents, and institutional investors in a range of transactions, such as ATM equity programs, confidentially marketed public offerings, registered direct offerings, PIPE offerings, committed equity facilities, convertible debt financings, and collateralized loan obligation (CLO) refinancings. She also has experience advising domestic and foreign issuers on SEC reporting, exchange listings, and corporate governance matters. She assists in drafting deal documents, conducting legal and disclosure diligence, managing the bring-down and closing process, and coordinating communication among multiple stakeholders.

Admissions

  • New York

Experience

  • Duane Morris LLP
    - Associate, 2025-present
  • Allen Overy Shearman Sterling LLP
    - Associate, 2024-2025

Education

  • Howard University School of Law, J.D., 2024
    -Vice President, African Law Students Association
  • Wake Forest University, B.A., 2019

Representative Matters

  • Represented the underwriters, led B. Riley Securities, Inc., in its capacity as representative of the several underwriters, in connection with the $230 million equity follow-on offering by Babcock & Wilcox Enterprises, Inc. (NYSE: BW), a globally-focused energy technologies provider with nearly 160 years of experience delivering diversified energy and emissions control solutions to utilities, data centers, oil and gas, and other industries.

  • Represented BTIG, LCC, as representative of the several underwriters, in connection with the $22.3 million public offering of common stock by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, including suicidal depression and chronic pain, as well as critical care conditions.